Cargando…

Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C‐Registry

While direct‐acting antivirals (DAAs) cure chronic hepatitis C virus (HCV) infection in almost all patients, some patients remain at risk of liver disease despite HCV cure. In order to identify risk factors indicating liver‐related morbidity and death after viral cure, we included 6982 patients from...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tacke, Frank, Klinker, Hartwig, Boeker, Klaus H. W., Merle, Uta, Link, Ralph, Buggisch, Peter, Hüppe, Dietrich, Cornberg, Markus, Sarrazin, Christoph, Wedemeyer, Heiner, Berg, Thomas, Mauss, Stefan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426389/ https://www.ncbi.nlm.nih.gov/pubmed/35666055 http://dx.doi.org/10.1002/hep4.2015

Ejemplares similares

Weight Gain after Interferon-Free Treatment of Chronic Hepatitis C—Results from the German Hepatitis C-Registry (DHC-R)
por: Schlevogt, Bernhard, et al.
Publicado: (2021)

Alcohol and Cannabis Consumption Does Not Diminish Cure Rates in a Real-World Cohort of Chronic Hepatitis C Virus Infected Patients on Opioid Substitution Therapy—Data From the German Hepatitis C-Registry (DHC-R)
por: Christensen, Stefan, et al.
Publicado: (2019)

Prognostic impact of steatosis in the clinical course of chronic HCV infection—Results from the German Hepatitis C-Registry
por: Rau, Monika, et al.
Publicado: (2022)

Real‐world experience for the outcomes and costs of treating hepatitis C patients: Results from the German Hepatitis C-Registry (DHC-R)
por: Krüger, Kathrin, et al.
Publicado: (2022)

Inflammatory patterns in plasma associate with hepatocellular carcinoma development in cured hepatitis C cirrhotic patients
por: Owusu Sekyere, Solomon, et al.
Publicado: (2021)

Treatment of Naïve Patients with Chronic Hepatitis C Genotypes 2 and 3 with Pegylated Interferon Alpha and Ribavirin in a Real World Setting: Relevance for the New Era of DAA
por: Heidrich, Benjamin, et al.
Publicado: (2014)

Real-World Safety, Effectiveness, and Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Treated with Glecaprevir/Pibrentasvir: Updated Data from the German Hepatitis C-Registry (DHC-R)
por: Cornberg, Markus, et al.
Publicado: (2022)

Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry
por: Hinrichsen, Holger, et al.
Publicado: (2020)

Expert opinion on the treatment of patients with chronic hepatitis C
por: Zeuzem, S, et al.
Publicado: (2009)

Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial
por: Witthöft, Th, et al.
Publicado: (2007)

Long-Lasting Imprint in the Soluble Inflammatory Milieu Despite Early Treatment of Acute Symptomatic Hepatitis C
por: Khera, Tanvi, et al.
Publicado: (2021)

Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study
por: Hofmann, Wolf Peter, et al.
Publicado: (2015)

Human γδ T Cell Receptor Repertoires in Peripheral Blood Remain Stable Despite Clearance of Persistent Hepatitis C Virus Infection by Direct-Acting Antiviral Drug Therapy
por: Ravens, Sarina, et al.
Publicado: (2018)

Evaluation of Point Shear Wave Elastography Using Acoustic Radiation Force Impulse Imaging for Longitudinal Fibrosis Assessment in Patients with HBeAg-Negative HBV Infection
por: Graf, Christiana, et al.
Publicado: (2019)

Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008–2019
por: Maisa, Anna, et al.
Publicado: (2021)

Corrigendum: Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008–2019
por: Maisa, Anna, et al.
Publicado: (2022)

PEG-IFN Alpha but Not Ribavirin Alters NK Cell Phenotype and Function in Patients with Chronic Hepatitis C
por: Markova, Antoaneta A., et al.
Publicado: (2014)

The New Era of Interferon-Free Treatment of Chronic Hepatitis C
por: Solbach, Philipp, et al.
Publicado: (2015)

Chronic hepatitis C virus infection irreversibly impacts human natural killer cell repertoire diversity
por: Strunz, Benedikt, et al.
Publicado: (2018)

Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors – Results from the PAN Study
por: Stahmeyer, Jona T., et al.
Publicado: (2016)

Clinical long-term outcome of hepatitis D compared to hepatitis B monoinfection
por: Wranke, Anika, et al.
Publicado: (2023)

Prevalence of Hepatitis B, C, and D in Germany: Results From a Scoping Review
por: Sperle, Ida, et al.
Publicado: (2020)

Additional challenges in reaching hepatitis C elimination goals in Germany due to the COVID-19 pandemic - descriptive analysis of drug prescription data from January 2018 to June 2021
por: Meyer, Emily D., et al.
Publicado: (2023)

Hepatitis C new drugs
por: Wedemeyer, H
Publicado: (2010)

Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting
por: Wiegand, Steffen B., et al.
Publicado: (2015)

Type I Interferon Elevates Co-Regulatory Receptor Expression on CMV- and EBV-Specific CD8 T Cells in Chronic Hepatitis C
por: Owusu Sekyere, Solomon, et al.
Publicado: (2015)

Spontaneous Cure of Acute Hepatitis C
por: ROSU, A.F., et al.
Publicado: (2015)

Hepatitis D virus infection: Pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022
por: Lampertico, Pietro, et al.
Publicado: (2023)

Eligibility and Safety of Triple Therapy for Hepatitis C: Lessons Learned from the First Experience in a Real World Setting
por: Maasoumy, Benjamin, et al.
Publicado: (2013)

Hepatitis B Surface Antigen Concentrations in Patients with HIV/HBV Co-Infection
por: Jaroszewicz, Jerzy, et al.
Publicado: (2012)

Barriers to initiation of hepatitis C virus therapy in Germany: A retrospective, case-controlled study
por: Buggisch, Peter, et al.
Publicado: (2021)

Irreversible impact of chronic hepatitis C virus infection on human natural killer cell diversity
por: Strunz, Benedikt, et al.
Publicado: (2018)

Successes and Challenges on the Road to Cure Hepatitis C
por: Horner, Stacy M., et al.
Publicado: (2015)

Hepatitis C: the challenges to link patients to the cure
Publicado: (2019)

Hepatitis C virus: Current steps toward elimination in Germany and barriers to reaching the 2030 goal
por: Sarrazin, Christoph, et al.
Publicado: (2021)

Hepatitis C cure as a ‘gathering’: Attending to the social and material relations of hepatitis C treatment
por: Farrugia, Adrian, et al.
Publicado: (2022)

Hepatitis C and Metabolic Disorders: Genetics, Mechanism, and Therapies (Clinical and Experimental)
por: Alvares-da-Silva, Mario Reis, et al.
Publicado: (2012)

1981. Real-World Data on Safety and Effectiveness of Glecaprevir/Pibrentasvir for the Treatment of Patients With Chronic Hepatitis C Virus Infection on Opioid Substitution Therapy: Latest Results from the German Hepatitis C-Registry
por: Reimer, Jens, et al.
Publicado: (2018)

Hepatitis C RNA assay differences in results: Potential implications for shortened therapy and determination of Sustained Virologic Response
por: Cloherty, Gavin, et al.
Publicado: (2016)

Implementation of hepatitis C cure in Australia: one year on
por: Richmond, Jacqueline A, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jkja5kk4nhd1fer2i7vpkt2bb8